Literature DB >> 16621898

Perturbation of glucose flux in the liver by decreasing F26P2 levels causes hepatic insulin resistance and hyperglycemia.

Chaodong Wu1, Salmaan A Khan, Li-Jen Peng, Honggui Li, Steven G Carmella, Alex J Lange.   

Abstract

Hepatic insulin resistance is one of the characteristics of type 2 diabetes and contributes to the development of hyperglycemia. How changes in hepatic glucose flux lead to insulin resistance is not clearly defined. We determined the effects of decreasing the levels of hepatic fructose 2,6-bisphosphate (F26P(2)), a key regulator of glucose metabolism, on hepatic glucose flux in the normal 129J mice. Upon adenoviral overexpression of a kinase activity-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, the enzyme that determines F26P(2) level, hepatic F26P(2) levels were decreased twofold compared with those of control virus-treated mice in basal state. In addition, under hyperinsulinemic conditions, hepatic F26P(2) levels were much lower than those of the control. The decrease in F26P(2) leads to the elevation of basal and insulin-suppressed hepatic glucose production. Also, the efficiency of insulin to suppress hepatic glucose production was decreased (63.3 vs. 95.5% suppression of the control). At the molecular level, a decrease in insulin-stimulated Akt phosphorylation was consistent with hepatic insulin resistance. In the low hepatic F26P(2) states, increases in both gluconeogenesis and glycogenolysis in the liver are responsible for elevations of hepatic glucose production and thereby contribute to the development of hyperglycemia. Additionally, the increased hepatic gluconeogenesis was associated with the elevated mRNA levels of peroxisome proliferator-activated receptor-gamma coactivator-1alpha and phosphoenolpyruvate carboxykinase. This study provides the first in vivo demonstration showing that decreasing hepatic F26P(2) levels leads to increased gluconeogenesis in the liver. Taken together, the present study demonstrates that perturbation of glucose flux in the liver plays a predominant role in the development of a diabetic phenotype, as characterized by hepatic insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621898     DOI: 10.1152/ajpendo.00126.2006

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  16 in total

Review 1.  Mechanisms of Insulin Action and Insulin Resistance.

Authors:  Max C Petersen; Gerald I Shulman
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

2.  Targeted overexpression of inducible 6-phosphofructo-2-kinase in adipose tissue increases fat deposition but protects against diet-induced insulin resistance and inflammatory responses.

Authors:  Yuqing Huo; Xin Guo; Honggui Li; Hang Xu; Vera Halim; Weiyu Zhang; Huan Wang; Yang-Yi Fan; Kuok Teong Ong; Shih-Lung Woo; Robert S Chapkin; Douglas G Mashek; Yanming Chen; Hui Dong; Fuer Lu; Lai Wei; Chaodong Wu
Journal:  J Biol Chem       Date:  2012-05-03       Impact factor: 5.157

3.  A role for PFKFB3/iPFK2 in metformin suppression of adipocyte inflammatory responses.

Authors:  Ting Qi; Yanming Chen; Honggui Li; Ya Pei; Shih-Lung Woo; Xin Guo; Jiajia Zhao; Xiaoxian Qian; Joseph Awika; Yuqing Huo; Chaodong Wu
Journal:  J Mol Endocrinol       Date:  2017-07       Impact factor: 5.098

4.  Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease.

Authors:  Zoltan Derdak; Charles H Lang; Kristine A Villegas; Ming Tong; Nicholas M Mark; Suzanne M de la Monte; Jack R Wands
Journal:  J Hepatol       Date:  2010-09-06       Impact factor: 25.083

Review 5.  Hormonal regulation of hepatic glucose production in health and disease.

Authors:  Hua V Lin; Domenico Accili
Journal:  Cell Metab       Date:  2011-07-06       Impact factor: 27.287

6.  Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of peroxisome proliferator-activated receptor gamma activation in mice.

Authors:  Xin Guo; Kefeng Xu; Jifeng Zhang; Honggui Li; Weiyu Zhang; Huan Wang; Alex J Lange; Y Eugene Chen; Yuqing Huo; Chaodong Wu
Journal:  J Biol Chem       Date:  2010-05-24       Impact factor: 5.157

7.  Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response.

Authors:  Xin Guo; Honggui Li; Hang Xu; Vera Halim; Laura N Thomas; Shih-Lung Woo; Yuqing Huo; Y Eugene Chen; Joseph M Sturino; Chaodong Wu
Journal:  J Nutr Biochem       Date:  2012-07-26       Impact factor: 6.048

8.  A role for inducible 6-phosphofructo-2-kinase in the control of neuronal glycolysis.

Authors:  Honggui Li; Xin Guo; Hang Xu; Shih-Lung Woo; Vera Halim; Caurnel Morgan; Chaodong Wu
Journal:  J Nutr Biochem       Date:  2012-12-14       Impact factor: 6.048

9.  Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response.

Authors:  Yuqing Huo; Xin Guo; Honggui Li; Huan Wang; Weiyu Zhang; Ying Wang; Huaijun Zhou; Zhanguo Gao; Sucheta Telang; Jason Chesney; Y Eugene Chen; Jianping Ye; Robert S Chapkin; Chaodong Wu
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

10.  Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans.

Authors:  Satish C Kalhan; Elisabetta Bugianesi; Arthur J McCullough; Richard W Hanson; David E Kelley
Journal:  Metabolism       Date:  2008-03       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.